CA2176298A1 - A single high dose fluoroquinolone treatment - Google Patents

A single high dose fluoroquinolone treatment

Info

Publication number
CA2176298A1
CA2176298A1 CA002176298A CA2176298A CA2176298A1 CA 2176298 A1 CA2176298 A1 CA 2176298A1 CA 002176298 A CA002176298 A CA 002176298A CA 2176298 A CA2176298 A CA 2176298A CA 2176298 A1 CA2176298 A1 CA 2176298A1
Authority
CA
Canada
Prior art keywords
high dose
single high
treatment
fluoroquinolone
fluoroquinolone treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002176298A
Other languages
French (fr)
Other versions
CA2176298C (en
Inventor
Dennis D. Copeland
Kathleen M. Ewert
Terry S. Wollen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23971311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2176298(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of CA2176298A1 publication Critical patent/CA2176298A1/en
Application granted granted Critical
Publication of CA2176298C publication Critical patent/CA2176298C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

The present invention relates to treatment of animals with fluoroquinolones. More specifically, the present invention relates to the use of fluoroqunolones in a single high dose to replace multiple lower doses.
CA002176298A 1995-06-27 1996-05-10 A single high dose fluoroquinolone treatment Expired - Lifetime CA2176298C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49611795A 1995-06-27 1995-06-27
US08/496,117 1995-06-27

Publications (2)

Publication Number Publication Date
CA2176298A1 true CA2176298A1 (en) 1996-12-28
CA2176298C CA2176298C (en) 2009-01-27

Family

ID=23971311

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002176298A Expired - Lifetime CA2176298C (en) 1995-06-27 1996-05-10 A single high dose fluoroquinolone treatment

Country Status (3)

Country Link
US (1) US5756506A (en)
CA (1) CA2176298C (en)
MX (1) MX9602442A (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000209A1 (en) * 1999-06-29 2001-01-04 Smithkline Beecham Corporation Methods of use of fluoroquinolone compounds against bacteria
CA2281817C (en) * 1999-06-29 2008-07-29 Smithkline Beecham Corporation Methods of use of fluoroquinolone compounds against maxillary sinus pathogenic bacteria
US20050032813A1 (en) * 1999-09-14 2005-02-10 Jacques Dubois Methods of use of fluoroquinolone compounds against maxillary sinus pathogenic bacteria
US6872723B2 (en) * 2002-01-28 2005-03-29 Wyeth Stabilized difloxacin injectable solution
US7439268B2 (en) * 2003-07-18 2008-10-21 Idexx Laboratories Compositions containing prodrugs of florfenicol and methods of use
DE102004054873A1 (en) * 2004-11-12 2006-05-18 Bayer Healthcare Ag Treatment of mastitis
DE102005055385A1 (en) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Medicines for hygienic application in the ear
MX2007006908A (en) * 2004-12-09 2007-08-03 Bayer Healthcare Ag Stabilisation of glucocorticoid esters with acids.
US8524734B2 (en) * 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070196398A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone fatty acid salt compositions
US20070197548A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
US7973022B2 (en) * 2006-02-17 2011-07-05 Idexx Laboratories, Inc. Fluoroquinolone carboxylic acid salt compositions
US7550625B2 (en) * 2007-10-19 2009-06-23 Idexx Laboratories Esters of florfenicol
EP2282746B8 (en) * 2008-03-27 2015-12-09 Caladrius Biosciences, Inc. Compositions and methods using stem cells in cutaneous wound healing
US8080550B2 (en) * 2008-08-01 2011-12-20 Alpha Synergy Development, Inc. Anesthetic compositions and methods of use
KR20110091510A (en) 2008-10-07 2011-08-11 엠펙스 파마슈티컬즈, 인코포레이티드 Aerosol fluoroquinolone formulations for improved pharmacokinetics
CA2739893C (en) 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
PL2473170T3 (en) 2009-09-04 2020-03-31 Horizon Orphan Llc Use of aerosolized levofloxacin for treating cystic fibrosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
DE3420116A1 (en) * 1984-05-30 1985-12-05 Bayer Ag, 5090 Leverkusen IMMUNTIMULATING AGENTS

Also Published As

Publication number Publication date
MX9602442A (en) 1997-02-28
US5756506A (en) 1998-05-26
CA2176298C (en) 2009-01-27

Similar Documents

Publication Publication Date Title
CA2176298A1 (en) A single high dose fluoroquinolone treatment
MX9602683A (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutically active substances.
AU1808595A (en) 3,8-diazabicyclo{3.2.1}octane derivatives having analgesic activity
CA2195213A1 (en) Use of droloxifene for the treatment of cardiovascular diseases
NO20053106D0 (en) Oral, extended-release analgesic dosage form.
CA2218714A1 (en) Dosage form comprising oxybutynin
MX9605023A (en) Imidazolidine-2,4-dione substituted compounds, as pharmaceutically active substances.
ITRM920412A0 (en) HETEROPROSTANOIDS, PROCEDURE FOR THEIR PREPARATION AND THEIR THERAPEUTIC USE.
CA2262566A1 (en) Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect
CA2189916A1 (en) A new regime for paclitaxel in kaposi's sarcoma patients
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
BG101401A (en) Cisaspide extended release oral compositions
EP0641207A4 (en) Enantiomeric cynemicin analogs, preparation and use thereof.
MX9708394A (en) Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation.
EP0601909A3 (en) Dibekacin derivatives and arbekacin derivatives active against resistant bacteria, and the production thereof.
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments
HUP9600665A2 (en) Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
CA2260863A1 (en) Treatment of psychotic disorders
CA2066532A1 (en) Pharmaceutical compositions
AU8268491A (en) Phosphonopyrrolidine- and piperidine-containing pseudopeptides of the statin type, a process for their preparation and their use as medicaments against retroviruses
ES2065855A1 (en) Desoxyazaphospholipid derivatives having inhibiting activity on phospholipase a2
IL134039A0 (en) Polyhydroxybutylpyrazines, their preparation and medicines containing them
PL321757A1 (en) Fungicidal azaheterocycloalkenes

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160510